ECKERT-&-ZIEGLER
14.4.2021 12:01:13 CEST | Business Wire | Press release
Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite with a total area of around 270 m² will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals and be operational from the first quarter of 2022. Together with a new U.S. based cGMP facility, Eckert & Ziegler will be able to provide radiopharmaceutical development services to companies looking for Europe, US and worldwide contract manufacturing.
“We have decided to make this investment to meet the growing global demand for radiopharmaceutical services in both imaging and therapy products. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate cancer," explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. “The new cGMP facility enables positioning as a European production and development partner for specialized pharmaceutical companies and innovative scientists. We offer them a wide range of radiopharmaceutical services under GLP and cGMP conditions."
The new cGMP suite, will enable Eckert & Ziegler to offer complete early development services, including process development and scale-up, CMC manufacturing, product release, stability programs and packaging. The company will be able to manufacture products on a clinical scale for phases I, II and III as well as for commercial use as a radiopharmaceutical contract manufacturer.
Eckert & Ziegler has a global presence as one of the leading partners of the radiopharmaceutical industry and has production and sales sites in 13 countries in Europe, North and South America and Asia.
In Wilmington (MA), USA, a production plant is currently being completed to manufacture Yttrium-90 solution for liver cancer treatment. In the future, the company will expand its European production capacity for Lutetium-177 labeled drugs to its U.S. site. Lutetium-177 is a coveted active ingredient in many new cancer therapy drugs. "Due to the large number of studies in which Lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. Our production sites in Europe, Asia and North America ideally position Eckert & Ziegler to meet this demand," adds Dr. Lutz Helmke.
In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
About Eckert & Ziegler Medical
The Medical segment of Eckert & Ziegler pools expertise from various areas to provide a comprehensive range of products and services for nuclear medicine, brachytherapy and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005367/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logitech Announces Q2 Fiscal Year 2027 Results27.10.2026 21:05:00 CET | Press release
Second Quarter Marks Company’s Eleventh Consecutive Quarter of Growth SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2027. Sales were $1.22 billion, up 3 percent in US dollars and 2 percent in constant currency, compared to Q2 of the prior year. GAAP gross margin was 44.9 percent, up 150 basis points compared to Q2 of the prior year. Non-GAAP gross margin was 45.2 percent, up 140 basis points compared to Q2 of the prior year. GAAP operating income was $201 million, up 5 percent compared to Q2 of the prior year. Non-GAAP operating income was $231 million, up 0.4 percent compared to Q2 of the prior year. GAAP earnings per share (EPS) was $1.25, up 9 percent compared to Q2 of the prior year. Non-GAAP EPS was $1.51, up 4 percent compared to Q2 of the prior year. Cash flow from operations was $164 million. The quarter-ending cash balance was $1.51 billio
Grid Dynamics Launches Business Process Consulting Practice to Bridge the Gap Between AI Investment and Business Results27.10.2026 21:05:00 CET | Press release
Key Takeaways: Grid Dynamics expands its enterprise AI transformation capabilities with a new Business Process Consulting practice enabling end-to-end AI transformation for Fortune 1000 enterprises. Integrated with Grid Dynamics' established AI engineering expertise, the practice helps enterprises identify business opportunities, provides investment justification to technology implementation and measurable value realization by enterprise-wide change management. The practice combines Grid Dynamics' ARC (Assess, Reengineer, Capture) methodology with a technology-driven approach to consulting, incorporating advanced AI capabilities into business process optimization and personalized, AI-powered change management. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced the launch of its Business Process Consulting practice, extending the company's AI transformation capabilities across the entire AI adoption li
Hightouch Partners with Independent Media to Activate Reader and Commercial Data27.10.2026 17:01:00 CET | Press release
The partnership will help Independent Media deliver more relevant reader engagement, build premium advertising audiences, and support affiliate and e-commerce growth. Hightouch, the leading agentic marketing platform, today announced a partnership with Independent Media, publisher of The Independent. Independent Media will use Hightouch to connect its customer data to marketing tools. With Hightouch, the company will send readers more relevant membership and subscription offers, build stronger audiences for its advertising partners, and grow its affiliate and e-commerce business. “Deepening customer relationships and delivering real value to our commercial partners requires moving seamlessly from insight to action,” said Krishan Gandhi, Director of Data Intelligence and Monetisation at Independent Media. “Partnering with Hightouch allows us to utilise our warehouse data directly into our engagement tools, powering real-time, omnichannel journey orchestration, while enabling us to build
IFF Identifies Ten Consumer Moments Reshaping Food and Beverage Innovation in the GLP-1 Era27.10.2026 16:00:00 CET | Press release
New research reveals how smaller, more intentional eating occasions are creating new opportunities for nutrition, flavor and renewed enjoyment. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, today launched its latest report, “GLP-1 Consumer Moments of Opportunity.” The report uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026614988/en/ New report from IFF uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. “What GLP-1 users need from food and beverage products depends on the moment, and those needs can change many times throughout the day,” said Yuvraj Arora, president of IFF Taste. “The most successful innovations will be designed around the occasions that matter most to consumers, delivering the right balance of nutrition
Phison Receives Micron Global Supplier Awards27.10.2026 15:00:00 CET | Press release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, is honored to announce that it was presented with Outstanding Supplier Performance Awards in the Semiconductor category and the Best in Quality – Assembly and Test categoryat the Micron Supplier Day 2026. The event, held in Boise, Idaho, United States was attended by top-level management of Micron and its suppliers, including Phison. The awards highlight our commitment to excellence in quality, innovation and collaboration with Micron, a global leader in semiconductor memory and storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027158504/en/ Phison wins Outstanding Supplier Performance Award in Semiconductor category and the Best in Quality – Assembly and Test category at the Micron Supplier Day 2026 “Receiving our third Micron Supplier Award in a row is a tremendous honor and a testament to the strength of our partnership
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom